BMD at 48 months was strongly correlated with baseline, but women who had received denosumab maintained higher BMD than the placebo group.
在第48个月，骨密度与基线高度相关，但经过狄诺塞麦治疗的妇女骨密度一直高于安慰剂组。
BMD at 48 months was strongly correlated with baseline, but women who had received denosumab maintained higher BMD than the placebo group.
在第48个月，骨密度与基线高度相关，但经过狄诺塞麦治疗的妇女骨密度一直高于安慰剂组。
应用推荐